Trial Profile
A Phase I, Open-label, Randomised, Single-centre, 2-way Crossover Bioequivalence Study Comparing 2 Formulations of Imeglimin After Single Oral Doses in Healthy Caucasian Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2019
Price :
$35
*
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Poxel
- 10 Jan 2019 Status changed from not yet recruiting to completed.
- 31 Aug 2018 New trial record